RPG Life Sciences Q4: Profit Slumps Despite Strong Revenue Growth

reported a contrasting Q4 performance on a consolidated YoY basis, with profit plunging 74.5% to ₹29.9 crore compared to ₹117.4 crore last year. The sharp decline was largely due to significantly lower exceptional gains, which stood at just ₹1.1 crore versus ₹109.9 crore in the previous year. However, the company posted healthy revenue growth of 23.6%, reaching ₹176.9 crore from ₹143.1 crore, indicating steady business momentum. Despite the weak profitability, the stock saw strong buying interest, jumping over 13% on April 30, 2025, reflecting notable market activity following the results announcement. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.